PPL - 138

Discover the journey behind our foundation, growth, and breakthroughs in pharmaceutical innovation.

Introducing PPL-138

Phoenix PharmaLabs has collaborated with scientists at the University of Bath (UK) in the development of a portfolio of 25 Nociceptin compounds including the drug that we now call PPL-138. This compound meets all of our criteria for a potent, safe, non-addicting analgesic for effective treatment of moderate to severe pain.

It has demonstrated long duration of action, effective bioavailability in sublingual administration and no development of tolerance after four weeks of chronic administration. Since PPL-138 has such a long duration of action, it has excellent potential as a non-addictive treatment for chronic and acute pain.

Morphine, Oxycodone, Hydracodone, Methadone, Fentanyl, etc. – and Heroin agonizes the Mu receptor.

OTHER OPIOIDS

The Solution: PPL-138

The Solution: PPL-138 provides highly effective pain relief with very low risk of abuse, addiction, overdose & other opioid side effects

PPL-138 partially stimulates NOP (Nociceptin) and Mu receptors

Scientific Partners

Studies of the drugs have been conducted by prominent scientists at leading institutions including Florida Atlantic University (FAU), the University of Bath (UK), Charles River Labs, ICON, the University of Texas, Wake Forest University, SRI International, Torrey Pines Institute for Molecular Studies, ITR Canada and, and the University of Montreal.

Go to Top